GLUL and hepatocellular carcinoma: In hepatocellular carcinoma (HCC), activating mutations in β-catenin increase the expression of the glutamate transporter (EAAT2, also known as SLC1A2), as well as of glutamine synthetase (Cadoret et al., 2002; Dal Bello et al., 2010).